May 3rd 2024
The biosimilars month in review reflects ongoing efforts to address key challenges in rheumatic disease treatment.
Advancing Care in Erosive Esophagitis: Towards a Path of Complete Healing
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Infliximab Biosimilars Show Promise, Equal Treatment Persistence in Treating IBD
September 14th 2023An analysis of the Phoenix cohort provides insight into responder rates and treatment persistence with infliximab biosimilars among those with no previous exposure to biologics, a previous failure to respond to biologics, or those switching from reference infliximab.
No Increase in Disease Activity, Treatment Discontinuation with Switch to Biosimilar Etancercept
September 13th 2023Use of etanercept biosimilars was not associated with an increased likelihood of treatment discontinuation or disease activity among people with rheumatoid arthritis relative to continuing treatment with originator etanercept.
Juliana Reed, MS: Enhancing Efficiency and Global Consistency in Biosimilar Development
Several key initiatives designed to streamline and enhance the efficiency of biosimilar development in the US market are underway, underscoring the timeliness of the Biosimilars Forum's recent report.
Advancing Access to Affordable Treatment: The US Launch of Adalimumab-adbm
Stephen Pagnotta, executive director and Biosimilar commercial lead at Boehringer Ingelheim, discusses the significance of the US launch of biosimilar adalimumab-adbm and its interchangeable designation.
No Difference in Pediatric Growth Rates with Infliximab Biosimilar vs Reference Agent
July 21st 2023A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease.